Maintaining Hold on Alkermes: Weighing Solid Performance Against Seasonal Slowdown and Pipeline Uncertainties
JPMorgan Adjusts Price Target on Alkermes to $32 From $31, Maintains Neutral Rating
A Quick Look at Today's Ratings for Alkermes(ALKS.US), With a Forecast Between $32 to $38
Alkermes Price Target Raised to $37.00/Share From $35.00 by HC Wainwright & Co.
Alkermes Analyst Ratings
Analysts' Opinions Are Mixed on These Healthcare Stocks: Alkermes (ALKS) and Viking Therapeutics (VKTX)
Strong Performance and Clinical Promise Uphold Buy Rating for Alkermes With $32 Target Price
Buy Rating for Alkermes Supported by Strong Q2 Performance and Promising Pipeline Potential
Alkermes Analyst Ratings
Alkermes Analyst Ratings
Alkermes Analyst Ratings
Alkermes Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Roche Holding AG (OtherRHHVF), MacroGenics (MGNX) and Alkermes (ALKS)
Stifel Nicolaus Reaffirms Their Hold Rating on Alkermes (ALKS)
Alkermes Analyst Ratings
Alkermes Buy Rating Affirmed on Strong Commercial Performance and Promising Drug Pipeline
Analysts Have Conflicting Sentiments on These Healthcare Companies: Pfizer (PFE), Sagimet Biosciences, Inc. Class A (SGMT) and Alkermes (ALKS)
Alkermes Hold Rating Justified by Mixed Financial Performance and Uncertain Pipeline Prospects
Maintaining Hold on Alkermes Amidst Modest Q1 Performance and Pipeline Prospects
Analysts Are Bullish on These Healthcare Stocks: Atricure (ATRC), Alkermes (ALKS)